Interventional Radiology—Review Article
Radioembolisation of liver metastases
David Boshell,
Lourens Bester,
Corresponding Author
David Boshell
Department of Radiology, St Vincent's Hospital, Sydney, New South Wales, Australia
Correspondence
Dr David Boshell, Department of Radiology, St Vincent's Hospital Sydney, Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.
Email: [email protected]
Search for more papers by this authorLourens Bester
Department of Radiology, University of Notre Dame, Sydney, New South Wales, Australia
Search for more papers by this authorDavid Boshell,
Lourens Bester,
Corresponding Author
David Boshell
Department of Radiology, St Vincent's Hospital, Sydney, New South Wales, Australia
Correspondence
Dr David Boshell, Department of Radiology, St Vincent's Hospital Sydney, Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.
Email: [email protected]
Search for more papers by this authorLourens Bester
Department of Radiology, University of Notre Dame, Sydney, New South Wales, Australia
Search for more papers by this authorFirst published: 21 June 2023
D Boshell: MBBS, FRANZCR; L Bester MBChB, MMed RAD (D), FRANZCR, FACP.
Summary
This review aims to present contemporary data for SIRT in the treatment of secondary hepatic malignancies including colorectal, neuroendocrine, breast and uveal melanoma.
Conflict of interest
DB is a consultant to Sirtex Medical. LB is a prior consultant to Sirtex Medical. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilised in the production of this manuscript.
Open Research
Data availability statement
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
References
- 1Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 2012; 35: 91–9.
- 2Helmberger T, Golfieri R, Pech M et al. Clinical application of trans-arterial Radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol 2021; 44: 21–35.
- 3Smits MLJ, Elschot M, van den Bosch MA et al. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies. J Nucl Med 2013; 54: 2093–100.
- 4Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med 2019; 7: 609.
- 5Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021; 325: 669–85.
- 6Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic liver disease: indications for Locoregional therapy and supporting data. Semin Interv Radiol 2017; 34: 145–66.
- 7Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res 2018; 11: 264–73.
- 8Tejpar S, Stintzing S, Ciardiello F et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017; 3: 194–201.
- 9Morris VK, Kennedy EB, Baxter NN et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2022; 41: 678–700. https://doi.org/10.1200/JCO.22.01690.
- 10Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol 2015; 33: 1809–24.
- 11Modest DP, Ricard I, Heinemann V et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016; 27: 1746–53.
- 12Kawazoe A, Shitara K, Fukuoka S et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 2015; 15: 258.
- 13Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619–26; discussion 626–627.
- 14Kawaguchi Y, Kopetz S, Newhook TE et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res 2019; 25: 5843–51.
- 15Wang J, Shen J, Huang C, Cao M, Shen L. Clinicopathological significance of BRAFV600E mutation in colorectal cancer: an updated meta-analysis. J Cancer 2019; 10: 2332–41.
- 16Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I. Real-world outcomes of patients with BRAF-mutated metastatic colorectal cancer treated in the United States. J Natl Compr Canc Netw 2022; 20: 144–50.
- 17Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol 2019; 10: 1274–98.
- 18Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644–57; discussion 657–658.
- 19Wasan HS, Gibbs P, Sharma NK et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18: 1159–71.
- 20Mulcahy MF, Mahvash A, Pracht M et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, Phase III trial. J Clin Oncol 2021; 39: 3897–907.
- 21Hendlisz A, den Eynde MV, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres Radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687–94.
- 22Gibbs P, Heinemann V, Sharma NK et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer 2018; 17: e617–29.
- 23Wasan H, Sharma R, Heinemann V et al. FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis. Ann Oncol 2017; 28: v615.
- 24Fernández-Montes A, Grávalos C, Pericay C et al. Current options for third-line and beyond treatment of metastatic colorectal cancer. Spanish TTD group expert opinion. Clin Colorectal Cancer 2020; 19: 165–77.
- 25Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909–19.
- 26Grothey A, Cutsem EV, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
- 27Saxena A, Bester L, Shan L et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol 2014; 140: 537–47.
- 28White J, Carolan-Rees G, Dale M et al. Analysis of a National Programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol 2019; 31: 58–66.
- 29Emmons EC, Bishay S, Du L et al. Survival and toxicities after 90Y Transarterial Radioembolization of metastatic colorectal cancer in the RESIN registry. Radiology 2022; 305: 228–36.
- 30Schmoll HJ, Cutsem EV, Stein A et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–516.
- 31Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007–16.
- 32Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985–92.
- 33Garlipp B, Gibbs P, Van Hazel GA et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg 2019; 106: 1837–46.
- 34Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB 2022; 24: 152–60.
- 35Baltatzis M, Siriwardena AK. Liver resection for colorectal hepatic metastases after systemic chemotherapy and selective internal radiation therapy with Yttrium-90 microspheres: a systematic review. Dig Surg 2019; 36: 273–80.
- 36Yamashita S, Sakamoto Y, Yamamoto S et al. Efficacy of preoperative portal vein embolization among patients with hepatocellular carcinoma, biliary tract cancer, and colorectal liver metastases: a comparative study based on single-center experience of 319 cases. Ann Surg Oncol 2017; 24: 1557–68.
- 37Sandström P, Røsok BI, Sparrelid E et al. ALPPS improves Resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis. Ann Surg 2018; 267: 833–40.
- 38Del Basso C, Gaillard M, Lainas P et al. Current strategies to induce liver remnant hypertrophy before major liver resection. World J Hepatol 2021; 13: 1629–41.
- 39Teo JY, Allen JC, Ng DC et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB. 2016; 18: 7–12.
- 40Ahmed A, Stauffer JA, LeGout JD et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure. J Gastrointest Oncol 2021; 12: 751–61.
- 41Wong TY, Zhang KS, Gandhi RT et al. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer 2022; 22: 224.
- 42Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors—a single-institution experience. J Gastrointest Oncol 2019; 10: 118–27.
- 43Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol 2018; 100: 23–9.
- 44Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol 2020; 12: 228–36.
- 45Davisson NA, Bercu ZL, Friend SC et al. Predictors of survival after Yttrium-90 Radioembolization of chemotherapy-refractory hepatic metastases from breast cancer. J Vasc Interv Radiol 2020; 31: 925–33.
- 46Alexander H, Wen D, Chu M et al. Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. Br J Radiol 2022; 95: 20210200.
- 47Aedo-Lopez V, Gérard CL, Boughdad S et al. Safety and efficacy of Ipilimumab plus Nivolumab and sequential selective internal radiation therapy in hepatic and extrahepatic metastatic uveal melanoma. Cancer 2022; 14: 1162.
- 48Levey AO, Elsayed M, Lawson DH et al. Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 Radioembolization. Cardiovasc Intervent Radiol 2020; 43: 254–63.
- 49Abbas H, Erridge S, Sodergren MH et al. Breast cancer liver metastases in a UK tertiary Centre: outcomes following referral to tumour board meeting. Int J Surg 2017; 44: 152–9.
- 50Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 2017; 7: 45411.
- 51Rivera K, Jeyarajah DR, Washington K. Hepatectomy, RFA, and other liver directed therapies for treatment of breast cancer liver metastasis: a systematic review. Front Oncol 2021; 11: 643383.
- 52Liu C, Tadros G, Smith Q et al. Selective internal radiation therapy of metastatic breast cancer to the liver: a meta-analysis. Front Oncol 2022; 12: 887653.
- 53 Locoregional Therapy for Liver Metastases From Breast Cancer. https://fyra.io. Endovascular Today. [Accessed 31 Oct 2022.] Available from URL: https://evtoday.com/articles/2018-jan/locoregional-therapy-for-liver-metastases-from-breast-cancer.
- 54Chang J, Charalel R, Noda C et al. Liver-dominant breast cancer metastasis: a comparative outcomes study of chemoembolization versus Radioembolization. Anticancer Res 2018; 38: 3063–8.
- 55Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 2021; 23: 43.
- 56Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335–42.
- 57Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68: 471–87.
- 58Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr 2020; 9: 44051–451.
- 59Ramdhani K, Braat AJAT. The evolving role of Radioembolization in the treatment of neuroendocrine liver metastases. Cancer 2022; 14: 3415.
- 60Currie BM, Nadolski G, Mondschein J et al. Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: Transarterial chemoembolization versus Transarterial Radioembolization. J Vasc Interv Radiol 2020; 31: 1627–35.
- 61Tomozawa Y, Jahangiri Y, Pathak P et al. Long-term toxicity after Transarterial Radioembolization with Yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29: 858–65.
- 62Su YK, Mackey RV, Riaz A et al. Long-term hepatotoxicity of Yttrium-90 Radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28: 1520–6.
- 63Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30: 1915–23.
- 64Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther 2018; 6: 87–104.
- 65Fallico M, Raciti G, Longo A et al. Current molecular and clinical insights into uveal melanoma (review). Int J Oncol 2021; 58: 10.
- 66Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB 2020; 22: 497–505.
- 67Edelhauser G, Schicher N, Berzaczy D et al. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. AJR Am J Roentgenol 2012; 199: 1387–92.
- 68Winter H, Rassam J, Virdee PS et al. Hepatic resection following selective internal radiation therapy for colorectal cancer metastases in the FOXFIRE clinical trial: clinical outcomes and distribution of microspheres. Cancer 2019; 11: E1155.
- 69Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc Intervent Radiol 2022; 45: 1608–21.
- 70Ilhan H, Goritschan A, Paprottka P et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in Radioembolization of primary and secondary hepatic tumors. J Nucl Med 2015; 56: 1654–60.
- 71Hermann AL, Dieudonné A, Ronot M et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with Transarterial Radioembolization with 90Y in the SARAH study. Radiology 2020; 296: 673–84.
- 72Garin E, Tselikas L, Guiu B et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 17–29.
- 73Levillain H, Duran Derijckere I, Marin G et al. 90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI Res 2018; 8: 60.
- 74Sankhla T, Cheng B, Nezami N et al. Role of resin microsphere Y90 dosimetry in predicting objective tumor response, survival and treatment related toxicity in surgically Unresectable colorectal liver metastasis: a retrospective single institution study. Cancer 2021; 13: 4908.
- 75Alsultan AA, van Roekel C, Barentsz MW et al. Dose-response and dose-toxicity relationships for glass 90Y Radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med Off Publ Soc Nucl Med 2021; 62: 1616–23.
- 76Cheng B, Sethi I, Davisson N et al. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nucl Med Commun 2021; 42: 402–9.
- 77Levillain H, Bagni O, Deroose CM et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48: 1570–84.
- 78Salem R, Padia SA, Lam M et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2022; 17: 328–43.
